Fulgent Genetics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q3 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Fulgent Genetics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2015 to Q2 2024.
  • Fulgent Genetics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$2.12M, a 31.7% increase year-over-year.
  • Fulgent Genetics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $7.01M.
  • Fulgent Genetics, Inc. annual Income Tax Expense (Benefit) for 2023 was $1.15M, a 97.3% decline from 2022.
  • Fulgent Genetics, Inc. annual Income Tax Expense (Benefit) for 2022 was $42.1M, a 75.9% decline from 2021.
  • Fulgent Genetics, Inc. annual Income Tax Expense (Benefit) for 2021 was $175M, a 141% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $7.01M -$2.12M +$986K +31.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $6.03M -$327K +$4.87M +93.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-03
Q4 2023 $1.15M -$10.9M -$1.48M -15.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $2.63M $20.3M +$19.9M +4810% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-03
Q2 2023 -$17.3M -$3.11M -$5.76M -217% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 -$11.5M -$5.2M -$53.6M -111% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q4 2022 $42.1M -$9.39M -$56.5M -120% Oct 1, 2022 Dec 31, 2022 10-K 2023-02-28
Q3 2022 $98.6M $414K -$37.1M -98.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $136M $2.65M -$20.9M -88.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 $157M $48.4M -$18.1M -27.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $175M $47.1M -$11.4M -19.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 $186M $37.5M +$23M +158% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-28
Q2 2021 $163M $23.6M +$24.2M Apr 1, 2021 Jun 30, 2021 10-K 2023-02-28
Q1 2021 $139M $66.5M +$66.5M +195526% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-28
Q4 2020 $72.5M $58.6M +$58.6M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 $13.9M $14.5M +$14.5M +23713% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$542K -$599K -$606K -8657% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 $64K $34K +$21K +162% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q4 2019 $43K -$38K -$926K -104% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 $969K $61K +$379K Jul 1, 2019 Sep 30, 2019 10-K 2021-03-08
Q2 2019 $590K $7K +$107K Apr 1, 2019 Jun 30, 2019 10-K 2021-03-08
Q1 2019 $483K $13K +$447K Jan 1, 2019 Mar 31, 2019 10-K 2021-03-08
Q4 2018 $36K $888K +$1.48M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$1.45M -$318K +$97K +23.4% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-13
Q2 2018 -$1.55M -$100K +$10K +9.09% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-13
Q1 2018 -$1.56M -$434K -$540K -509% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-13
Q4 2017 -$1.02M -$596K -$1.1M -218% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-22
Q3 2017 $84K -$415K -$832K -200% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-22
Q2 2017 $916K -$110K -$110K Apr 1, 2017 Jun 30, 2017 10-K 2019-03-22
Q1 2017 $1.03M $106K +$106K Jan 1, 2017 Mar 31, 2017 10-K 2019-03-22
Q4 2016 $920K $503K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-20
Q3 2016 $417K +$417K Jul 1, 2016 Sep 30, 2016 10-K 2018-03-20
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 $0 Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q3 2015 $0 Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.